Business
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
Dr. Lotan’s distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada’s NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Yair Lotan, MD, a
About this update from Relmada Therapeutics, Inc.
[{"type":"image","alt":"Relmada Therapeutics","displaySize":"","headline":null,"caption":"Relmada Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":130,"height":33,"url":"https://media.zenfs.com/en/globenewswire.com/864e8ce076842deb8ff51dcb2351bb2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ttP74diEks8HOrImNeTk.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/864e8ce076842deb8ff51dcb2351bb2e","width":130,"height":33}},"lazy":false},{"type":"text","content":"Dr. Lotan’s distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada’s NDV-01 program","length":144,"tagName":"p"},{"type":"text","content":"Phase 3 trial for NDV-01 expected to begin in H1 2026","length":53,"tagName":"p"},{"type":"text","content":"CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada’s Clinical Advisory Board (CAB). Dr. Lotan’s deep expertise in bladder cancer care and clinical research will be invaluable as Relmada prepares to initiate a Phase 3 trial for NDV-01 in H1 2026, building on positive Phase 2 data, presented at the American Urology Association 2025 Annual Meeting (AUA 2025) on April 28, 2025.","length":681,"tagName":"p"},{"type":"text","content":"Dr. Lotan brings more than two decades of experience in bladder cancer care, clinical development and academic medicine. As a nationally recognized expert in molecular biomarkers, with involvement in the establishment of practice guidelines for the management of bladder cancers and health economics research, Dr. Lotan is well suited to Chair Relmada’s Clinical Advisory Board and to help shape the clinical development strategy for NDV-01.","length":441,"tagName":"p"},{"type":"text","content":"“We believe that Yair’s first-hand understanding of the current treatment challenges in bladder cancer, combined with his deep clinical development expertise, will help to strengthen and enrich the clinical development program for NDV-01,” said Sergio Traversa, Chief Executive Officer, Relmada. “A...